Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-cash Items (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Non-cash Items for 9 consecutive years, with $501.3 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 227.86% to $501.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $501.3 million through Dec 2025, up 227.86% year-over-year, with the annual reading at $501.3 million for FY2025, 227.86% up from the prior year.
  • Non-cash Items hit $501.3 million in Q4 2025 for Protagonist Therapeutics, up from $152.9 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $501.3 million in Q4 2025 to a low of $1.7 million in Q2 2022.
  • Historically, Non-cash Items has averaged $91.9 million across 5 years, with a median of $60.0 million in 2023.
  • Biggest five-year swings in Non-cash Items: tumbled 99.02% in 2022 and later skyrocketed 5323.53% in 2023.
  • Year by year, Non-cash Items stood at $102.7 million in 2021, then plummeted by 93.28% to $6.9 million in 2022, then skyrocketed by 769.57% to $60.0 million in 2023, then soared by 154.83% to $152.9 million in 2024, then surged by 227.86% to $501.3 million in 2025.
  • Business Quant data shows Non-cash Items for PTGX at $501.3 million in Q4 2025, $152.9 million in Q4 2024, and $60.0 million in Q4 2023.